Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 643,800 shares, a decline of 27.8% from the September 30th total of 891,600 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 330,300 shares, the short-interest ratio is presently 1.9 days. Based on an average daily volume of 330,300 shares, the short-interest ratio is presently 1.9 days. Currently, 0.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently modified their holdings of FMS. Crossmark Global Holdings Inc. raised its stake in Fresenius Medical Care AG & Co. KGaA by 0.9% in the 1st quarter. Crossmark Global Holdings Inc. now owns 64,871 shares of the company’s stock worth $1,615,000 after purchasing an additional 584 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 5.9% during the third quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock worth $275,000 after purchasing an additional 585 shares during the period. Yousif Capital Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.8% in the second quarter. Yousif Capital Management LLC now owns 9,804 shares of the company’s stock valued at $280,000 after buying an additional 625 shares in the last quarter. Callan Capital LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.6% in the first quarter. Callan Capital LLC now owns 13,974 shares of the company’s stock valued at $348,000 after buying an additional 870 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% in the second quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after buying an additional 896 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on FMS. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Price Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $24.30 on Wednesday. The company has a market capitalization of $14.26 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 0.64 and a beta of 0.92. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $19.89 and a 12 month high of $30.46. The stock’s 50 day moving average is $26.05 and its 200-day moving average is $26.59.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The business had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $4.72 billion. Equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.